Literature DB >> 28592125

Correlation of Gankyrin oncoprotein overexpression with histopathological grade in prostate cancer.

M M Riahi, N S Sistani, P Zamani, K Abnous, K Jamialahmadi.   

Abstract

Prostate cancer is the second most commonly diagnosed cancer among men worldwide. Identifying new prognostic and predictive biomarkers will help stratification of prostate cancer patients for a better treatment. Gankyrin is a novel oncoprotein which regulates cell cycle and protein degradation. Gankyrin overexpression correlated with the malignant phenotypes and promotes the tumorigenicity and metastasis in many cancers. However, there are not any reports on the role of Gankyrin in prostate cancer. Therefore, this study was designed to investigate the expression of Gankyrin in prostate cancer and analyze its correlation with some clinicopathological characteristics. We characterized the expression of gankyrin in fifty five prostate cancer specimens and twenty non-cancerous tissues by immunohistochemical staining and the results were correlated with clinical characteristics and pathological parameters.Results showed that Gankyrin was expressed in 41 of 55 (74%) prostate cancer patients and its expression was significantly higher than corresponding adjacent normal tissues (p<0.001). Gankyrin overexpression was significantly correlated with histopathological tumor grade, Gleason score and tumor differentiation (P=0.002). These findings showed that Gankyrin is mainly overexpressed in high grade prostate tumors so it may have a significant role in prostate cancer progress and it May serve as a useful biomarker for the identification of aggressive prostate cancers.

Entities:  

Keywords:  Gankyrin; immunohistochemistry oncoprotein.; prostate cancer

Mesh:

Substances:

Year:  2017        PMID: 28592125     DOI: 10.4149/neo_2017_511

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  4 in total

Review 1.  Gankyrin as a potential target for tumor therapy: evidence and perspectives.

Authors:  Haixai Li; Junyan Zhang; Cheng Zhen; Baojun Yang; Limin Feng
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

2.  Gankyrin Drives Malignant Transformation of Gastric Cancer and Alleviates Oxidative Stress via mTORC1 Activation.

Authors:  Bo Huang; Weiyang Cai; Qian Wang; Feng Liu; Ming Xu; Yanjie Zhang
Journal:  Oxid Med Cell Longev       Date:  2018-10-21       Impact factor: 6.543

3.  KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling.

Authors:  Jihua Han; Fengyue Wang; Yaliang Lan; Jiabei Wang; Chunlei Nie; Yingjian Liang; Ruipeng Song; Tongsen Zheng; Shangha Pan; Tiemin Pei; Changming Xie; Guangchao Yang; Xirui Liu; Mingxi Zhu; Yan Wang; Yao Liu; Fanzheng Meng; Yifeng Cui; Bo Zhang; Yufeng Liu; Xianzhi Meng; Jiewu Zhang; Lianxin Liu
Journal:  Oncogene       Date:  2018-08-16       Impact factor: 9.867

4.  LMX1B-associated gankyrin expression predicts poor prognosis in glioma patients.

Authors:  Xu Guo; Haozhe Piao; Yixue Xue; Yunhui Liu; Hongyu Zhao
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.